Fatal outcome after combined therapy for myeloblastic leukaemia and toxoplasmosis.
D001344:Autopsy; D001853:Bone Marrow / Q000187:drug effects*; D001854:Bone Marrow Cells; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use; D003630:Daunorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D011739:Pyrimethamine / Q000009:adverse effects* / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000188:drug therapy*
D003561:Cytarabine; D002955:Leucovorin; D011739:Pyrimethamine; D003630:Daunorubicin